Try a new search

Format these results:

Searched for:

person:rubens02

in-biosketch:true

Total Results:

4


Hereditary Diffuse Gastric Cancer: One Family's Story [Meeting Abstract]

Zylberberg, Haley; Rubin, Steven D
ISI:000395764604095
ISSN: 1572-0241
CID: 2577862

Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease

Zlatanic, Jusuf; Korelitz, Burton I; Rajapakse, Ramona; Kim, Peter S; Rubin, Steven D; Baiocco, Peter J; Panagopoulos, Georgia
PURPOSE: 6-Mercaptopurine (6-MP) has proven efficacy in the therapy of inflammatory bowel disease. Its teratogenicity is demonstrated in animal studies when used at very high doses, whereas human data suggest that 6-MP at maintenance doses is safe. We report the outcome of 72 pregnancies in patients with inflammatory bowel disease who were previously treated with 6-MP with three different doses of 50, 75, and 100 mg/d, for a median duration of 18 months, along with long-term follow-up of the children. METHODS: We have compared the outcome of pregnancies and development of the offspring in the following two groups: group 1, patients with inflammatory bowel disease who conceived 6 months to 22 years after stopping 6-MP (median 72 months); and group 2, patients with inflammatory bowel disease who never received 6-MP prior to conception. All pregnancies were evaluated in terms of outcome: live full-term birth, premature delivery, stillbirth, spontaneous abortion, ectopic pregnancy, and therapeutic dilatation and curettage. Data on children were obtained regarding birth weight, congenital anomalies, and development. RESULTS: Group 1 included 72 pregnancies carried by 29 women. There were 51 live births (4 premature), 16 spontaneous abortions, 1 stillbirth, 2 therapeutic abortions due to abnormal amniocentesis, and 2 ectopic pregnancies. The total incidence of fetal loss was 29.2%. In group 2, 75 women had 140 pregnancies resulting in 120 live births (8 premature), 18 spontaneous abortions, and 2 stillbirths. There were no cases of ectopic pregnancies or abnormal amniocentesis. The total incidence of fetal loss was 14.3%. There was no increase in the incidence of developmental defects when the mothers had been treated with 6-MP prior to pregnancy. CONCLUSIONS: The incidence of fetal loss is higher in women with inflammatory bowel disease who had been previously treated with 6-MP compared with those who had not. Whether this was related to the older age at conception in 6-MP group, longer duration of disease, initially more severe disease, or use of 6-MP we cannot tell
PMID: 12642735
ISSN: 0192-0790
CID: 65348

Immunomodulator therapy: Targeting severe inflammatory bowel disease

Rubin, SD; Korelitz, BI
Immunomodulator therapy for more severe or poorly responsive inflammatory bowel disease leg, Crohn's disease and ulcerative colitis) primarily focuses on use of corticosteroids, mercaptopurine, azathioprine, cyclosporine, and methotrexate. The purpose of this type of therapy is to influence various aspects of the immune response, rather than just the inflammation. Immunomodulatory therapy can be used for first-line, short-term relief of severe inflammation (corticosteroids), for chronic therapy to maintain remissions (the 6-mercaptopurine [6-MP] agents, mercaptopurine and azathioprine), and to produce responses in patients refractory to high-dose corticosteroids (IV cyclosporine A) or with Crohn's disease refractory to 6-MP (methotrexate). This article reviews the pharmacology of each treatment option and results of clinical trials and presents the authors' recommended first- and second-line treatments
ISI:A1995TK96700011
ISSN: 1082-801x
CID: 688602

INTRAVENOUS CORTICOTROPIN VERSUS HYDROCORTISONE IN THE TREATMENT OF CROHNS-DISEASE [Meeting Abstract]

CHADI, RM; CHUN, A; COLONNA, T; FELDER, JB; JACKSON, MH; MORGENSTERN, EH; RUBIN, SD; SACKNOFF, AG; GLEIM, G; KORELITZ, BI
ISI:A1995QT86303166
ISSN: 0016-5085
CID: 688612